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Abstract
Introduction—Placental transfer of amino acids via amino acid transporters is essential for fetal 
growth. Little is known about the epigenetic regulation of amino acid transporters in placenta. This 
study investigates the DNA methylation status of amino acid transporters and their expression 
across gestation in human placenta.
Methods—BeWo cells were treated with 5-aza-2′-deoxycytidine to inhibit methylation and 
assess the effects on amino acid transporter gene expression. The DNA methylation levels of 
amino acid transporter genes in human placenta were determined across gestation using DNA 
methylation array data. Placental amino acid transporter gene expression across gestation was also 
analysed using data from publically available Gene Expression Omnibus data sets. The expression 
levels of these transporters at term were established using RNA sequencing data.
Results—Inhibition of DNA methylation in BeWo cells demonstrated that expression of specific 
amino acid transporters can be inversely associated with DNA methylation. Amino acid 
transporters expressed in term placenta generally showed low levels of promoter DNA 
methylation. Transporters with little or no expression in term placenta tended to be more highly 
methylated at gene promoter regions. The transporter genes SLC1A2, SLC1A3, SLC1A4, 
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SLC7A5, SLC7A11 and SLC7A10 had significant changes in enhancer DNA methylation across 
gestation, as well as gene expression changes across gestation.
Conclusion—This study implicates DNA methylation in the regulation of amino acid transporter 
gene expression. However, in human placenta, DNA methylation of these genes remains low 
across gestation and does not always play an obvious role in regulating gene expression, despite 
clear evidence for differential expression as gestation proceeds.
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Introduction
The placenta selectively mediates transfer of nutrients to the fetus, which is vital for optimal 
fetal development. Impaired placental amino acid transport results in reduced fetal growth 
[1, 2], which is associated with increased risk of adulthood disease [3]. Regulation of amino 
acid transporters occurs in response to short-term maternal stimuli [4], but could also occur 
across longer timescales. Epigenetic modification provides a potential mechanism for 
regulation of placental amino acid transporters, mediating early environmental influences 
across gestation [5]. The placenta has a unique DNA methylation profile with large regions 
of hypomethylation, containing developmental and tissue specific genes, interspersed with 
regions of high methylation [6]. The extent of epigenetic regulation by DNA methylation of 
functionally related genes such as amino acid transporters is unclear.
Accumulative, uniporter and facilitated amino acid transporters act in a coordinated way to 
transfer amino acids across the microvillous and basal plasma membrane (BM) of the 
placental syncytiotrophoblast [7, 8]. Placental amino acid metabolism also contributes to the 
rate of amino acid transfer [9, 10]. There are multiple classes of amino acid transporters, all 
of which are members of the SLC (solute carrier) gene series as outlined in Table 1 [11]. 
Accumulative transporters from the SLC1 (EAAT) [12], SLC7 (CAT) [15] and SLC38 
(SNAT) [13, 14] families transport maternal amino acids into the syncytiotrophoblast. 
Amino acids are exchanged between the intracellular and extracellular pools by antiporters 
from the SLC1 (ASC) and SLC7 (LAT, y+LAT) families [16]. SLC16A10 (TAT1), 
SLC43A1 (LAT3) and SLC43A2 (LAT4) encode the BM facilitated transporters that 
mediate net amino acid transfer to the fetus, with SLC16A10 expression correlating with 
fetal and neonatal growth [7, 17].
Expression and activity of specific placental amino acid transporters increase across 
gestation [18, 19], to help meet increasing fetal demand as gestation progresses [4, 20]. 
Maternal factors such as diet, smoking and vitamin D levels can alter placental amino acid 
transporter gene expression [17, 21], potentially via DNA methylation. Indeed, maternal 
nutrition [22], obesity [23], stress [24], toxin exposure [25] or smoking [26] during 
pregnancy, influence placental DNA methylation.
DNA methylation could mediate the placental adaptations to early exposures and increased 
fetal demand for nutrients across gestation [27]. Placentas from both small and large for 
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gestational age babies have altered methylation profiles for specific genes [28, 29]. In 
addition, global methylation in human placenta is reduced with gestational diabetes or 
preeclampsia and increased with maternal obesity [30, 31]. The early environment 
influences placental glucose transport, potentially by epigenetic regulation of human 
placental glucose transporters. Indeed, associations between DNA methylation and glucose 
transporter expression have previously been demonstrated across gestation [32–34].
Taken together these studies suggest that DNA methylation may have a role in regulating 
placental nutrient transport. We therefore investigated whether this epigenetic mechanism is 
involved in regulating amino acid transporters in the human placenta.
Methods
Amino acid transporter DNA methylation in BeWo and HEK293 cells
Cell culture—BeWo human choriocarcinoma cells from the HPA Culture Collections 
(Salisbury, UK) or Human Embryonic Kidney 293 cells (HEK293) were cultured in DMEM/
Ham’s F12 (1:1) media (with HEPES and L-glutamine, with phenol red) supplemented with 
500 iu/ml penicillin, 500 iu/ml streptomycin, 1 mM glutamine and 10% fetal bovine serum 
(FBS; All Lonza). Cells were cultured in 32 mm wells at a density of 2.5 x 105 at 37°C in a 
humidified incubator (5% CO2 in air). At 24 h cells were incubated with or without 7.5 μM 
5-aza-2′-deoxycytidine (5-AZA-dC; Sigma), a concentration previously shown to be 
effective in BeWo cells [35]. At 48 h RNA was extracted using RNAzol (Sigma-Aldrich, 
UK) with centrifugation and isopropanol precipitation. Each treatment was carried out in 
triplicate in three independent experiments.
Quantitative reverse transcription PCR (qRT-PCR)—RNA was quantified by UV 
absorption (NanoDrop 1000, Thermo Scientific, UK) and RNA integrity was confirmed by 
agarose gel electrophoresis. Total RNA (0.2 μg) was reverse transcribed into cDNA and gene 
expression was measured using qRT-PCR with a Roche Light-Cycler-480. Oligonucleotide 
probes were supplied by Roche (Universal Probe Library (UPL); Roche, UK) and primers 
supplied by Eurogentec (Seraing, Belgium): primer and probe details are listed in 
Supplementary Table I. For UPL probes cycle parameters were 95°C for 10 min; 45 cycles 
of 95°C for 10 s, 60°C for 30 s; then 72 °C for 1 s. For Perfect Probes the cycle parameters 
were 95°C for 10 min; 50 cycles of 95°C for 15 s, 50°C for 30 s and 72°C for 15 s. Intra-
assay CV’s for each gene were 5-8%.
The geNorm™ human Housekeeping Gene Selection Kit (Perfect Probe, Primer Design 
Limited, UK) was used to select reference genes for normalization of the qPCR data. 
Reference gene stability differed between BeWo, HEK293 and placenta, with UBC and 
GAPDH being the most stable genes common to all tissues (Supplementary Figure 1). 
GAPDH was affected by 5-AZA-dC treatment and was expressed at a higher level in the cell 
lines compared to placenta. UBC was selected as the reference gene for this study as it did 
not change expression with 5-AZA-dC treatment and showed similar expression levels in all 
three tissues (Supplementary Figure 1).
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Data analysis—mRNA levels are presented relative to UBC. Summary data are presented 
as mean (SEM). Data were log transformed if not normally distributed. Normally distributed 
data were analysed with a t-test and non-normally distributed data were analysed with a 
Mann-Whitney U test using SPSS® Statistics (Version 20, IBM, USA). A significant 
difference was accepted at p < 0.05. Data were converted to z-scores and a heatmap plotted 
using R version 3.3.2.
Human placental RNA sequencing
Placental samples—The study was conducted according to the guidelines in the 
Declaration of Helsinki, and the Southampton and South West Hampshire Research Ethics 
Committee approved all procedures. Written informed consent was obtained from all 
participating women. Placentas (n = 6) were collected from term pregnancies within 30 min 
of delivery. Villous samples (30 mg) were snap frozen in liquid nitrogen and stored at -80°C.
RNA Sequencing—RNA was extracted from placental samples using the miRNeasy mini 
kit with the RNase-free DNase Set (Qiagen, UK) according to manufacturer’s instructions. 
RNA was quantified by UV absorption (NanoDrop 1000, Thermo Scientific, UK). RNA 
quality was assessed with an RNA 2100 Bioanalyser (Agilent, USA) and accepted if the 
RNA integrity number (RIN) was above 6.0.
RNA samples (450 ng) were converted into cDNA libraries using the Illumina TruSeq 
Stranded mRNA sample preparation kit. Stranded RNA sequencing was carried out by 
Expression Analysis (Durham, USA) using HiSeq 2x50bp paired-end sequencing on an 
Illumina platform.
Data analysis—After sequencing, the analysis was performed by Expression Analysis 
using their in-house developed RNA-Seq bioinformatics pipeline (version 9) which uses a 
variety of internally developed and open source programs (https://
expressionanalysis.github.io/ea-utils/). Across all samples, the median number of reads was 
25.6 million following Quality Control analysis using the Expression Analysis/Quintiles in-
house developed tool: fastq-mcf3. Adjusted sequencing information was aligned against the 
human transcriptome to identify the genes within each sample using the aligner STAR 
version 2.4 which is specifically designed for RNA-Seq. Counts (number of reads 
overlapping each gene) are expressed as Fragments Per Kilobase of exon per Million reads 
(FPKMs). The counts of fragments were normalized by dividing by the total length of all 
exons in the gene (or transcript); per kilobase of exon. This value was normalized against the 
library size; per million read means. Data was expressed as mean log2 FPKMs.
Amino acid transporter gene DNA methylation analysis in human placentas
Illumina Infinium HumanMethylation27 BeadChip (HM27) array data—Genome-
scale DNA methylation analysis of 18 first trimester (elective abortion) and 14 third 
trimester normal placental villous tissue samples was performed using the HM27 array. Data 
was uploaded to the Gene Expression Omnibus (GEO), accession number GSE31781 [36]. 
We extracted amino acid transporter gene data from this DNA methylation data. The output 
presents methylation levels as beta values from 0 (unmethylated) to 1 (completely 
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methylated). Data were expressed as changes in methylation at term compared to first 
trimester by t-test. P values were adjusted for false discovery rate and a significant difference 
accepted at p < 0.05.
Illumina Infinium HumanMethylation450 BeadChip (HM450) array data—
Illumina Infinium HM450 array DNA methylation data from 5 first trimester and 10 third 
trimester chromosomally normal placental villous tissue samples was downloaded from 
GEO series GSE49343 [37]. We extracted data related to amino acid transporter genes from 
the DNA methylation data. Methylation levels are presented as beta values from 0 
(unmethylated) to 1 (completely methylated). For each transporter, mean methylation values 
were calculated for CpGs grouped by region: 5’ promoter CpG island, shore or shelf, gene 
body or enhancers determined by the ENCODE Consortium using informatics [38]. Data 
were expressed as changes in methylation at term compared to first trimester and analysed 
by t-test with Bonferroni correction (116 tests): a significant difference accepted at p < 4.3 x 
10-4.
Gene expression array data analysis in human placentas
Gene expression data from first trimester (≥ 12 weeks, n = 4) compared to term placenta 
(37-40 weeks, n = 4) and early second trimester (14-19 weeks, n = 14) compared to term 
(37-40 weeks, n = 9) placental samples were downloaded from GEO series GSE5999 [39] 
and GSE9984 [40] (Affymetrix Human Genome U133A). Data were compared between 
groups using the interactive web tool GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r). 
GEO2R performs comparisons on original submitter-supplied processed data tables using 
the GEOquery and limma (Linear Models for Microarray Analysis) R packages from the 
Bioconductor project. Data were normalized and expressed as log2 fold changes in gene 
expression at term compared to first or early second trimester. P values were adjusted for 
false discovery rate and a significant difference accepted at p < 0.05.
Results
This study aimed to investigate the DNA methylation and expression of 25 amino acid 
transporter genes (Table 1) in human placenta as follows. Accumulative transporter genes: 
SLC1A1, SLC1A2, SLC1A3, SLC1A6, and SLC1A7 (EAATs); SLC7A1 (CAT1); and 
SLC38A1, SLC38A2, SLC38A3, SLC38A4 and SLC38A6 (SNATs). Antiporter genes: 
SLC1A4 and SLC1A5 (ASCs); SLC7A5 and SLC7A8 (LATs); SLC7A6 and SLC7A7 (y
+LATs); SLC7A9, SLC7A10 and SLC7A11; and the auxiliary proteins SLC3A1, and 
SLC3A2. Facilitated transporter genes: SLC16A10, SLC43A1 and SLC43A2.
Disruption of DNA methylation influences amino acid transporter gene expression
Cell culture experiments were used to assess whether DNA methylation influences amino 
acid transporter gene expression. Of the 25 targeted amino acid transporter genes; SLC3A1, 
SLC38A3 and SLC38A6 were not measured. The trophoblast derived BeWo cells were 
incubated with 5-AZA-dC which inhibits DNA methyltransferase activity thus disrupting 
global DNA methylation levels. 5-AZA-dC treatment increased mRNA expression levels of 
SLC7A1, SLC7A6, SLC1A4, SLC1A5, SLC43A1, SLC43A2, SLC7A10, SLC3A2, 
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SLC7A8, SLC7A11, SLC1A3, SLC1A7 and SLC38A1 (Figure 1). Conversely, expression 
of SLC1A1 and SLC1A6 was reduced following 5-AZA-dC treatment in BeWo cells (Figure 
1). SLC16A10, SLC7A9, SLC38A2, SLC38A4 and SLC7A7 gene expression was not 
altered by 5-AZA-dC treatment (Figure 1). SLC1A2 and SLC7A5 mRNA expression could 
not be detected in BeWo cells that had not been 5-AZA-dC treated (but was detectable 
following 5-AZA-dC treatment). HEK293 cells did show expression of SLC1A2 and 
SLC7A5 that had not been 5-AZA-dC treated. HEK293 cells were therefore used to 
investigate the expression of these two transporters and showed upregulation following 5-
AZA-dC treatment (Figure 1).
Placental amino acid transporter genes show altered DNA methylation across gestation
HM27 array data—We examined the DNA methylation levels of 24 of the 25 targeted 
amino acid transporters in first trimester and term placenta using HM27 array data as 
SLC7A7 was not included in the array. Two probes targeted the promoter region of each 
gene except for SLC1A5 and SLC1A3 that were targeted by single probes. 39 out of the 46 
probes targeted CpGs within CpG islands (Supplementary Table 2).
12 out of 46 CpG sites measured showed significantly altered methylation across gestation. 
There was increased DNA methylation across gestation at individual CpGs (CpG 227 ± 70 
base pairs from transcription start site (TSS), Supplementary Table 2) in the following amino 
acid transporter genes: SLC1A3, SLC1A7, SLC38A1, SLC7A5, SLC3A2 and SLC7A9 
(Figure 2). There was decreased DNA methylation across gestation at specific sites (CpG 
533 ± 102 base pairs from transcription start site (TSS), Supplementary Table 2) in the 
following amino acid transporter genes: SLC7A1, SLC7A10, SLC3A1 and SLC7A11 
(Figure 2).
The 19 amino acid transporters studied that are known to be active in placenta [7] showed 
relatively low levels of promoter methylation (mean β-value 0.10) and high mRNA levels at 
term as measured by RNA sequencing (Figure 3). For 17 of these transporter genes the CpG 
sites measured were within CpG islands (Supplementary Table 2). The 5 amino acid 
transporters not known to be active in placenta (with lower mRNA levels) had relatively 
higher levels of promoter methylation (mean β-value 0.48) compared to active transporters p 
< 0.001, t-test (Figure 3). For 3 of these transporter genes the CpG sites measured were 
within CpG islands (Supplementary Table 2).
HM450 array data—To examine the DNA methylation levels of the 25 amino acid 
transporters in more detail within first trimester and term placenta we used publically 
available data from an HM450 methylation array. This array provides a much greater 
coverage of the genome in terms of CpG location, as well as covering 43 out of the 46 sites 
covered by the HM27 array. The number of probes targeting each transporter gene ranged 
from 6 to 46 and covered CpGs within the 5’ promoter CpG island, shore or shelf, gene 
body or ENCODE predicted enhancer elements.
At predicted enhancer sites DNA methylation across gestation was significantly increased in 
the amino acid transporter genes SLC1A2, SLC1A3, SLC1A7, SLC38A3, SLC38A4, 
SLC7A7, and SLC7A1; decreased in SLC43A2 and both increased and decreased in 
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enhancers of SLC7A5 and SLC7A8 (Table 2). CpGs in shore and shelf regions had 
increased DNA methylation across gestation in the amino acid transporter genes SLC1A1, 
SLC1A4, SLC38A2, SLC43A1 and SLC7A10 (Table 2). The promoter regions of SLC1A5 
and SLC7A1 had increased methylation across gestation, whereas SLC38A1 had both 
increased and decreased methylation in promoter regions (Table 2). CpG islands in the gene 
body of SLC7A9 showed increased methylation and that of SLC7A1 showed decreased 
methylation across gestation (Table 1).
Placental amino acid transporter genes show altered expression across gestation
We examined the gene expression of the 25 selected placental amino acid transporters (Table 
1) across gestation using publically available gene expression array data from first trimester, 
early second trimester and term placentas. The transporters SLC7A7, SLC38A6, SLC1A2, 
SLC1A3, SLC1A4 and SLC7A11 showed decreased gene expression across gestation, 
whereas the transporters SLC7A5, SLC38A2 and SLC7A10 showed increased gene 
expression across gestation. Of these transporters, SLC1A2, SLC1A3, SLC1A4, SLC7A11, 
SLC7A5, and SLC38A2 were observed to have altered methylation across gestation in the 
separate HM450 array cohort.
Discussion
This study investigated DNA methylation of amino acid transporter genes in the placenta. In 
a trophoblast derived cell line, we observed changes to the expression of specific amino acid 
transporters following inhibition of DNA methylation. However, it is unclear whether these 
observations are due to direct effects on DNA methylation within the transporter genes 
themselves or methylation of indirect regulatory factors. Cohort data revealed that promoter 
DNA methylation of the placental amino acid transporter genes remains low across gestation 
and does not always play an obvious role in regulating gene expression. For specific 
transporter genes there were changes in DNA methylation across gestation and these 
methylation changes were located in enhancer regions. Analysis of publically available gene 
expression array data from human placenta showed expression changes across gestation for 
these genes also. Together these data suggest that DNA methylation may play a role in the 
regulation of amino acid transporter gene expression.
The findings of this study support a role for DNA methylation in the maintenance of long-
term gene silencing [41] to determine whether a transporter is capable of being active in the 
placenta, rather than a mechanism for more subtle regulation of gene activity levels over 
time. This may act as a protective ‘buffer’ against potentially harmful methylation changes 
induced by exposure to adverse maternal environments and therefore be a protective 
mechanism for the fetus. For example, the amino acid transporters whose expression is 
absent or low in term placenta (as measured by RNA sequencing) were more highly 
methylated in term placenta at the promoter sites investigated using the HM27 methylation 
array. The amino acid transporter genes SLC1A6, SLC1A7 and SLC7A9 whose expression 
in human placenta is low [15, 42] tended to have consistently high levels of methylation 
across gestation. Indeed, inhibition of DNA methylation by 5-AZA-dC increased the 
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expression of both SLC1A6 and SLC1A7, supporting a role for methylation in controlling 
the expression of these genes.
Most of the amino acid transporters with higher expression in the placenta showed low 
levels of methylation at term at the promoter sites investigated using the HM27 methylation 
array. The majority of CpG dense promoters when assessed genome-wide remain 
unmethylated which is permissive of gene expression activity, along with the histone mark 
H3K4me3; however additional epigenetic marks such as H3K27ac in these regions are more 
indicative of gene transcription [43, 44]. Methylation may therefore play a role in 
determining whether a transporter is capable of being activated or permanently inactivated 
within human placenta, but not directly influence the precise expression level. However, 
there are likely to be more CpG sites involved in regulating the expression of these genes 
and potentially multiple start sites for transcription that could be invoked. DNA methylation 
is just part of the epigenetic machinery and there may also be other epigenetic processes 
involved [41].
The amino acid transporters SLC1A2 SLC1A3, SLC1A4, SLC7A5, SLC7A11 and 
SLC7A10 showed changes in DNA methylation across gestation. These transporters also 
showed changes in gene expression across gestation in publically available gene expression 
array data and an inverse relationship between methylation and expression in the BeWo cell 
culture experiments. SLC1A3 showed the same methylation changes in both DNA 
methylation arrays. These data suggest that the expression of only a small number of amino 
acid transporters in the human placenta may be mediated by DNA methylation in the 
predicted enhancer regions covered on the array; although the effect sizes were small and 
direct functional testing is required. This is in contrast to placental glucose transporters that 
have variable methylation levels, which are associated with changes in gene expression 
across gestation [34]. A limitation to this study is that RNA sequencing data was only 
available in term placentas and not across gestation, whereas array data was available for 
early gestation and term placentas to allow comparison. While there was little evidence for 
direct epigenetic regulation of amino acid transporter expression overall, the relatively small 
percentage of CpG sites covered by the array mean that evidence for epigenetic control at 
other sites may not have been observed.
The limited relationships between DNA methylation and amino acid transporter gene 
expression are likely to be indirect via coordinated higher-level control in a more dynamic 
state than would normally be associated with CpG island-containing promoter methylation, 
as measured by the 27K array [8]. Although those modifications that can be identified within 
CpG islands are strongly functionally supported to impact on gene activity [45]. CpG island 
shore locations (2k either side of the island) are seen to be the most dynamic with respect to 
their methylation state and significant with respect to their functional impact on expression 
[46]. Indeed, the associations we did observe tended to be in CpGs within these shore 
regions and enhancer regions covered by the 450K array but not covered on the 27k array 
platform. The location of the CpGs analysed within each gene may also be a limitation to 
this study as only limited information on the methylation status of the regions could be 
gained. Although there are many cases whereby nearby CpGs regions are co-ordinately 
regulated. The fact that the relationships across gestation for methylation and expression 
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were observed in array data from unrelated individuals and that we did not have details of 
the maternal environment, diet or anthropometric profile for the array samples were 
limitations of this study as we could not incorporate this into the analysis.
In these studies whole placental tissue was used for methylation and gene expression 
measures, however the cell heterogeneity within the placenta may influence these measures. 
We used BeWo cells for the DNA methylation experiments, which may have a different 
phenotype from term placenta as they originate from choriocarcinoma derived from invasive 
trophoblast. This model does however allow us to clearly see the effects of DNA methylation 
on gene expression in a trophoblast derived cell line.
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In summary, our findings do not support a major role for DNA methylation within gene 
regulatory sites in directly influencing temporal differential expression of amino acid 
transporter genes in human placenta throughout gestation. This supports the idea that 
DNA methylation is involved in the long-term/robust repression of particular genes, 
whilst the hypomethylated state indicates a permissive promoter that is able to be 
expressed when required.
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Figure 1. 
Heatmap representing amino acid transporter gene expression with and without 5-AZA-dC 
treatment in a) HEK293 cells and b) BeWo cells. Data presented as z-scores of relative 
mRNA expression clustered by expression pattern. n = 9 for both control and 5-AZA-dC 
treated cells. *p < 0.05, **p < 0.01, ***p < 0.001; treated group compared to control group. 
Data is for BeWo cell expression of all transporters except SLC1A2 and SLC7A5 whose 
mRNA expression could not be detected in BeWo cells that had not been 5-AZA-dC treated 
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(was detectable following 5-AZA-dC treatment). The expression of these two transporters 
was measured in HEK293 cells.
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Figure 2. Amino acid transporter gene DNA methylation across gestation
DNA methylation levels of 24 amino acid transporters in first trimester and term placenta 
measured using an HM27 array. Two probes targeted CpGs in the promoter region of each 
gene except for SLC1A5 and SLC1A3 that were targeted by single probes; # indicates the 
CpG was not within a CpG island. Data presented as mean ± SEM. * p < 0.05, significant 
difference in DNA methylation of transporter gene (in box) between early (n = 18) and term 
(n = 14) placentas.
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Figure 3. 
Term placenta amino acid transporter gene expression measured by RNA Sequencing vs. 
promoter DNA methylation. Each point is the mean value for a specific amino acid 
transporter type. Solid circles represent transporters expressed and active in human placenta; 
open circles represents transporters not thought to be active in term human placenta. (Two 
points per transporter as two probes per promoter in the methylation array). Copy number = 
Fragments Per Kilobase of exon per Million reads (FPKM); RNA-sequencing at 19 million 
reads.
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Table 1
Placental amino acid transporter gene expression change across gestation and summary of methylation 
changes
Amino acid transporter
1st trimester - 
term expression
2nd trimester - 
term expression
Methylation change 1st 
trimester - term
Cell meth/ex relationGene Protein Adj p val logFC Adj p val logFC
Expression
Change 27K array 450K array
SLC1A1 EAAT3 0.398 -0.174 0.086 -0.207 no no up same
SLC1A2 EAAT2 0.001* -0.548 0.306 -0.029 down no up opposite
SLC1A3 EAAT1 0.450 -0.033 0.002* -0.108 down up up opposite
SLC1A4 ASCT1 0.069 -0.096 0.029* -0.055 down no up opposite
SLC1A5 ASCT2 0.590 -0.028 0.488 -0.036 no no up opposite
SLC1A6 EAAT4 0.502 -0.040 0.996 0.000 no no no same
SLC1A7 EAAT5 0.096 -0.079 0.549 0.010 no up up opposite
SLC3A1 rBAT 0.205 -0.540 0.297 -0.043 no down down -
SLC3A2 4F2hc 0.153 0.082 0.190 0.071 no up no opposite
SLC7A1 CAT1 0.055* -0.134 0.165 0.053 down down down opposite
SLC7A5 LAT1 0.542 0.046 0.031* 0.107 up up up/down opposite
SLC7A6 y+LAT2 0.537 0.017 0.436 -0.020 no no no opposite
SLC7A7 y+LAT1 0.605 0.031 0.021* -0.060 down - up none
SLC7A8 LAT2 0.311 0.117 0.278 0.045 no no up/down opposite
SLC7A9 b(0,+)AT1 0.135 -0.083 0.865 0.009 no up up none
SLC7A10 asc 0.931 -0.008 0.031* 0.077 up down up opposite
SLC7A11 xCT 0.032* -0.166 0.595 0.020 down down up opposite
SLC16A10 TAT1 0.415 0.048 0.221 -0.047 no no no none
SLC38A1 SNAT1 0.092 0.077 0.124 0.055 no up up/down opposite
SLC38A2 SNAT2 0.025* 0.080 0.009* 0.079 up no up none
SLC38A3 SNAT3 0.852 -0.013 0.159 0.067 no no up -
SLC38A4 SNAT4 0.286 -0.060 0.232 0.032 no no up same
SLC38A6 SNAT6 0.088 -0.073 0.008* -0.19 down no no -
SLC43A1 LAT3 0.983 -0.002 0.107 0.044 no no up opposite
SLC43A2 LAT4 0.154 0.051 - - no no down opposite
Placental gene expression array data from first trimester (n = 4) compared to term (n = 4) and early second trimester (n = 14) compared to term (n = 
9) samples. Data downloaded from GEO series GSE5999 and GSE9984. *p < 0.05; methylation (meth), expression (ex).Shading indicates 
transporters thought to have low expression in placenta. Bold indicates transporters that the data supports a role for methylation in the regulation of 
gene expression.
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Table 2
Placental HM450 array DNA methylation data for amino acid transporter genes across 
gestation (1st trimester–term)
Amino acid transporter Mean 1st 
trimester 
methylation 
(beta units)
Mean term 
methylation 
(beta units)
Change (dB) p value Regulatory Feature Group Relation to Island Gene regionGene Protein
SLC1A1 EAAT3 0.08 0.08 -0.004 7.5E-01 Promoter Island 1stExon
SLC1A1 0.24 0.16 -0.080 1.9E-03 Promoter N_Shore Body
SLC1A1 0.63 0.84 0.207 2.8E-08* S_Shore Body
SLC1A2 EAAT2 0.16 0.25 0.090 1.0E-03 Island 5'UTR;1stExon
SLC1A2 0.22 0.29 0.076 1.3E-03 N_Shore Body
SLC1A2 0.62 0.76 0.143 7.6E-05* Enhancer Body
SLC1A2 0.71 0.90 0.185 2.4E-04* Enhancer 3'UTR
SLC1A3 EAAT1 0.08 0.08 0.004 6.1E-01 1stExon;5'UTR
SLC1A3 0.65 0.75 0.105 4.1E-07* Enhancer Body
SLC1A4 ASCT1 0.06 0.07 0.003 6.4E-01 Promoter Island 1stExon;5'UTR
SLC1A4 0.59 0.71 0.127 5.1E-04 Promoter S_Shore Body;5'UTR
SLC1A4 0.29 0.43 0.137 5.0E-06* N_Shore TSS1500
SLC1A4 0.81 0.80 -0.009 5.0E-01 Body;Body
SLC1A5 ASCT2 0.07 0.07 0.002 6.2E-01 Promoter Island 1stExon;5'UTR
SLC1A5 0.09 0.09 0.003 5.3E-01 Promoter S_Shore TSS1500
SLC1A5 0.08 0.16 0.086 1.0E-05* Promoter N_Shelf 1stExon;5'UTR
SLC1A5 0.13 0.14 0.013 2.3E-01 Promoter N_Shore TSS1500;Body
SLC1A5 0.59 0.53 -0.053 7.8E-04 N_Shore TSS1500;Body
SLC1A5 0.91 0.89 -0.023 5.8E-02 Body
SLC1A6 EAAT4 0.47 0.45 -0.017 4.0E-01 1stExon
SLC1A6 0.59 0.51 -0.083 1.7E-02 Body
SLC1A7 EAAT5 0.72 0.81 0.091 2.1E-04* 1stExon;5'UTR
SLC1A7 0.60 0.67 0.070 2.7E-04* Island Body
SLC1A7 0.83 0.84 0.010 6.7E-01 S_Shore Body
SLC1A7 0.82 0.85 0.022 7.5E-02 N_Shore Body
SLC1A7 0.63 0.74 0.117 7.9E-07* Enhancer Body
SLC3A1 rBAT 0.63 0.53 -0.105 6.3E-03 1stExon
SLC3A1 0.05 0.06 0.014 7.5E-03 Enhancer Body
SLC3A1 0.54 0.59 0.045 7.8E-02 Body
SLC3A2 4F2hc 0.07 0.07 0.005 8.1E-02 Promoter Body
SLC3A2 0.77 0.76 -0.005 6.7E-01 Promoter N_Shore Body
SLC3A2 0.89 0.86 -0.036 5.8E-04 Enhancer Body
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Amino acid transporter Mean 1st 
trimester 
methylation 
(beta units)
Mean term 
methylation 
(beta units)
Change (dB) p value Regulatory Feature Group Relation to Island Gene regionGene Protein
SLC3A2 0.09 0.05 -0.037 7.9E-03 Body
SLC7A1 CAT1 0.09 0.09 -0.003 8.5E-01 Promoter Island 5'UTR;1stExon
SLC7A1 0.65 0.71 0.061 8.1E-03 Enhancer 5'UTR
SLC7A1 0.69 0.71 0.025 3.8E-01 Promoter N_Shore 5'UTR
SLC7A1 0.43 0.40 -0.026 2.8E-01 S_Shelf Body
SLC7A1 0.60 0.54 -0.067 3.4E-05* Island Body
SLC7A1 0.68 0.71 0.035 1.2E-01 Body
SLC7A1 0.68 0.65 -0.030 2.2E-01 Island 3'UTR
SLC7A1 0.61 0.71 0.099 1.9E-03 N_Shelf 3'UTR
SLC7A1 0.05 0.08 0.030 2.4E-02 N_Shore 3'UTR
SLC7A5 LAT1 0.07 0.11 0.042 1.7E-03 Promoter Island 1stExon
SLC7A5 0.14 0.17 0.030 1.3E-02 Enhancer Body
SLC7A5 0.72 0.74 0.026 2.4E-01 Island Body
SLC7A5 0.45 0.54 0.088 1.6E-04* Enhancer S_Shore TSS1500
SLC7A5 0.23 0.30 0.074 2.3E-03 N_Shore Body
SLC7A5 0.59 0.70 0.112 1.0E-04* N_Shelf Body
SLC7A5 0.80 0.72 -0.080 1.2E-04* Body
SLC7A5 0.88 0.93 0.054 1.6E-03 Enhancer 3'UTR
SLC7A5 0.88 0.88 0.001 8.6E-01 3'UTR
SLC7A6 y+LAT2 0.06 0.06 0.001 8.2E-01 Promoter Island 5'UTR
SLC7A6 0.11 0.11 0.001 9.2E-01 Promoter S_Shore 5'UTR
SLC7A6 0.92 0.90 -0.017 4.7E-01 S_Shelf 5'UTR
SLC7A6 0.92 0.90 -0.011 2.2E-01 Promoter N_Shore TSS1500
SLC7A7 y+LAT1 0.35 0.34 -0.012 5.5E-01 5'UTR;1stExon
SLC7A7 0.19 0.26 0.069 5.9E-03 TSS1500;5'UTR
SLC7A7 0.85 0.81 -0.039 4.9E-02 TSS1500;5'UTR
SLC7A7 0.12 0.13 0.013 5.7E-01 N_Shelf 1stExon;5'UTR
SLC7A7 0.20 0.19 -0.006 7.7E-01 N_Shore TSS200
SLC7A7 0.32 0.42 0.099 6.1E-03 Enhancer N_Shore TSS1500
SLC7A7 0.58 0.54 -0.045 3.5E-01 Body
SLC7A7 0.38 0.49 0.109 1.2E-04* Enhancer Body
SLC7A8 LAT2 0.08 0.08 -0.001 9.3E-01 5'UTR;1stExon
SLC7A8 0.74 0.68 -0.060 2.6E-04* Enhancer 5'UTR;1stExon
SLC7A8 0.72 0.69 -0.033 3.4E-03 Enhancer Body;TSS1500
SLC7A8 0.63 0.72 0.090 2.6E-07* Enhancer Body
SLC7A8 0.89 0.91 0.021 1.3E-01 3'UTR
SLC7A9 b(0,+)AT1 0.40 0.46 0.062 1.7E-02 1stExon;5'UTR
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Amino acid transporter Mean 1st 
trimester 
methylation 
(beta units)
Mean term 
methylation 
(beta units)
Change (dB) p value Regulatory Feature Group Relation to Island Gene regionGene Protein
SLC7A9 0.73 0.82 0.096 1.4E-04* Island Body;Body
SLC7A9 0.80 0.81 0.012 5.4E-01 N_Shore Body;Body
SLC7A9 0.82 0.85 0.023 7.3E-02 S_Shore Body;Body
SLC7A10 asc 0.10 0.09 -0.008 5.1E-01 Island TSS1500
SLC7A10 0.42 0.48 0.064 7.3E-05* S_Shelf Body
SLC7A10 0.42 0.53 0.110 4.3E-04* N_Shelf Body
SLC7A10 0.55 0.50 -0.045 5.6E-02 N_Shore Body
SLC7A10 0.60 0.70 0.103 1.9E-03 S_Shore 3'UTR;3'UTR
SLC7A11 xCT 0.07 0.08 0.005 5.3E-01 1stExon;5'UTR
SLC7A11 0.10 0.11 0.013 2.3E-01 Body
SLC7A11 0.78 0.74 -0.043 5.4E-04 Enhancer Body
SLC7A11 0.80 0.83 0.037 5.3E-05* Enhancer Body
SLC7A11 0.91 0.91 0.004 7.7E-01 Enhancer TSS1500
SLC16A10 TAT1 0.06 0.07 0.009 1.1E-01 Promoter Island
SLC16A10 0.81 0.81 0.005 8.0E-01 S_Shelf Body
SLC16A10 0.35 0.38 0.032 3.4E-02 Enhancer Body
SLC38A1 SNAT1 0.09 0.10 0.003 7.9E-01 Promoter Island 5'UTR
SLC38A1 0.36 0.56 0.205 3.7E-08* Promoter S_Shore TSS1500
SLC38A1 0.44 0.77 0.336 1.8E-07* N_Shelf 5'UTR
SLC38A1 0.18 0.21 0.025 2.0E-01 Promoter N_Shore 5'UTR
SLC38A1 0.90 0.88 -0.016 1.8E-02 Body
SLC38A1 0.93 0.90 -0.027 5.1E-05* Enhancer 3'UTR
SLC38A2 SNAT2 0.07 0.07 0.003 6.9E-01 Promoter Island 5'UTR
SLC38A2 0.41 0.40 -0.014 2.8E-01 Promoter S_Shore TSS1500
SLC38A2 0.66 0.79 0.128 5.2E-05* S_Shore TSS1500
SLC38A2 0.91 0.85 -0.053 9.0E-03 Promoter N_Shelf Body
SLC38A2 0.07 0.07 0.005 5.5E-01 Promoter N_Shore Body
SLC38A2 0.93 0.93 -0.001 9.6E-01 3'UTR
SLC38A3 SNAT3 0.08 0.08 0.008 1.3E-01 Island 5'UTR
SLC38A3 0.77 0.86 0.089 1.1E-03 S_Shelf 5'UTR
SLC38A3 0.51 0.75 0.235 8.0E-06* Enhancer N_Shore TSS1500
SLC38A4 SNAT4 0.10 0.11 0.011 8.6E-02 1stExon;5'UTR
SLC38A4 0.63 0.81 0.188 4.1E-06* Enhancer 5'UTR
SLC38A4 0.89 0.89 0.001 9.6E-01 Enhancer Body
SLC38A4 0.16 0.25 0.099 2.2E-04* Enhancer Body
SLC38A4 0.91 0.89 -0.022 8.4E-02 N_Shelf TSS1500
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Amino acid transporter Mean 1st 
trimester 
methylation 
(beta units)
Mean term 
methylation 
(beta units)
Change (dB) p value Regulatory Feature Group Relation to Island Gene regionGene Protein
SLC38A6 SNAT6 0.06 0.06 0.002 6.2E-01 Unclassified Island 5'UTR
SLC38A6 0.90 0.92 0.014 6.4E-02 Enhancer Body
SLC43A1 LAT3 0.12 0.11 -0.005 4.0E-01 Promoter Island 1stExon;5'UTR
SLC43A1 0.25 0.34 0.086 1.7E-03 Enhancer Body
SLC43A1 0.70 0.82 0.118 5.6E-06* S_Shelf Body
SLC43A1 0.07 0.08 0.012 3.3E-02 S_Shore Body
SLC43A1 0.53 0.59 0.062 7.4E-03 N_Shore Body
SLC43A2 LAT4 0.04 0.04 0.038 3.8E-02 Promoter 5'UTR
SLC43A2 0.63 0.52 -0.110 3.3E-08* Enhancer S_Shore Body
SLC43A2 0.59 0.58 -0.013 3.0E-01 N_Shore Body
SLC43A2 0.75 0.74 -0.013 3.5E-01 Body
SLC43A2 0.59 0.38 -0.208 1.4E-07* Enhancer Island 3'UTR
DNA methylation change across gestation. Bold indicates significance, * p < 4.3E-04.
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